RWD89 ASSESSING EARLY ADOPTION OF PULSED FIELD ABLATION FOR THE TREATMENT OF ATRIAL FIBRILLATION USING CLAIMS AND HOSPITAL CHARGE DATA

patients shifting to Rakan KKM due to financial toxicity over the period of 2026-2035.Costs were limited to drug costs for chemo-, endocrine, and anti-HER2 therapies.All costs and financial outcomes, including Rakan KKM profit and patient out-of-pocket savings, were discounted at 3% annually.Results: The patient shift could generate RM 38,063,229 (USD8,458,495, 1USD=RM4.50)cumulative profit for MOH over ten years.Patients who switch to Rakan KKM may save an average of RM 26,285 (USD5,841) in out-of-pocket costs, a 59.2% reduction compared to private cancer care cost.From a health system perspective, the simulated scenario (private + Rakan KKM) could potentially save RM 428,215,819 (USD95,159,070) over ten years, compared to the base case (private only).Conclusions: Rakan KKM has the potential to be a cost-saving co-payment model for breast cancer treatment access.It potentially offers substantial savings for patients, contributes to MOH sustainability, and reduces system-wide healthcare costs.